Armata Pharmaceuticals (ARMP) Free Cash Flow (2013 - 2026)
Armata Pharmaceuticals (ARMP) posted Free Cash Flow of -$5.8 million for Q1 2026, up 13.1% sequentially from -$6.7 million in Q4 2025, and up 23.88% YoY from -$4.7 million in Q1 2025.
Armata Pharmaceuticals (ARMP) Free Cash Flow (2013 - 2026) Analysis & Trends
Armata Pharmaceuticals has reported Free Cash Flow for 14 years, with the latest figure at -$5.8 million in Q1 2026.
- Quarterly Free Cash Flow rose 23.88% year-over-year to -$5.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$24.5 million (up 32.54% YoY) and the FY2025 annual result came in at -$26.3 million, up 33.29% from the prior year.
- Free Cash Flow climbed to -$5.8 million in Q1 2026 per ARMP's latest filing, from -$6.7 million in the prior quarter.
- Over five years, Free Cash Flow peaked at -$3.8 million in Q1 2022 and troughed at -$19.6 million in Q1 2023.
- A 5-year average of -$9.5 million and a median of -$9.3 million in 2022 frame the typical range for Free Cash Flow.
- The sharpest annual moves came in 2023 and 2025: Free Cash Flow sank 421.99% in 2023, then soared 50.67% in 2025.
- Over 5 years, Free Cash Flow stood at -$10.0 million in 2022, then retreated by 4.75% to -$10.5 million in 2023, then advanced by 25.28% to -$7.8 million in 2024, then climbed by 14.32% to -$6.7 million in 2025, then rose by 13.1% to -$5.8 million in 2026.
- According to Business Quant data, Free Cash Flow over the past three periods registered -$5.8 million, -$6.7 million, and -$4.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -563.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 437.80 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 292.04 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 433.84 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -95.09 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 477.44 Mn |
| 10 | Armata Pharmaceuticals | 182.82 Mn | 158.82 Mn | - | -8.68 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -8.68 Mn |
| Jun 30, 2026 | -8.68 Mn |
| Mar 31, 2026 | -5.85 Mn |
| Mar 31, 2026 | -5.85 Mn |
| Dec 31, 2025 | -6.73 Mn |
| Dec 31, 2025 | -6.73 Mn |
| Sep 30, 2025 | -4.54 Mn |
| Sep 30, 2025 | -4.54 Mn |
| Jun 30, 2025 | -7.36 Mn |
| Jun 30, 2025 | -7.36 Mn |
| Mar 31, 2025 | -7.68 Mn |
| Mar 31, 2025 | -7.68 Mn |
| Dec 31, 2024 | -7.85 Mn |
| Dec 31, 2024 | -7.85 Mn |
| Sep 30, 2024 | -9.20 Mn |
| Sep 30, 2024 | -9.20 Mn |
| Jun 30, 2024 | -11.54 Mn |
| Jun 30, 2024 | -11.54 Mn |
| Mar 31, 2024 | -10.83 Mn |
| Mar 31, 2024 | -10.83 Mn |